Third Wave Prepares to Test IPO Waters | GenomeWeb

NEW YORK, Jan 19 – Third Wave Technologies is planning to test the IPO waters with a roadshow that is scheduled to begin next week, a company spokeswoman said Friday.

The company is hoping to sell 8.5 million shares at $11 - $13 a share in an offering that could raise as much as $110 million for the Madison, Wis.-based maker of SNP analysis technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.